Transitional B cell cytokines predict renal allograft outcomes
- 24 February 2021
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (582)
- https://doi.org/10.1126/scitranslmed.abe4929
Abstract
Early immunological biomarkers that predict rejection and chronic allograft loss are needed to inform preemptive therapy and improve long-term outcomes. Here, we prospectively examined the ratio of interleukin-10 (IL-10) to tumor necrosis factor–α (TNFα) produced by transitional-1 B cells (T1B) 3 months after transplantation as a predictive biomarker for clinical and subclinical renal allograft rejection and subsequent clinical course. In both Training (n = 162) and Internal Validation (n = 82) Sets, the T1B IL-10/TNFα ratio 3 months after transplantation predicted both clinical and subclinical rejection anytime in the first year. The biomarker also predicted subsequent late rejection with a lead time averaging 8 months. Among biomarker high-risk patients, 60% had early rejection, of which 48% recurred later in the first posttransplant year. Among high-risk patients without early rejection, 74% developed rejection later in the first year. In contrast, only 5% of low-risk patients had early and 5% late rejection. The biomarker also predicted rejection in an External Validation Set (n = 95) and in key patient subgroups, confirming generalizability. Biomarker high-risk patients exhibited progressively worse renal function and decreased 5-year graft survival compared to low-risk patients. Treatment of B cells with anti-TNFα in vitro augmented the IL-10/TNFα ratio, restored regulatory activity, and inhibited plasmablast differentiation. To conclude, the T1B IL-10/TNFα ratio was validated as a strong predictive biomarker of renal allograft outcomes and provides a rationale for preemptive therapeutic intervention with TNF blockade.Keywords
Funding Information
- National Institutes of Health (R34 AI136782)
- American Society of Transplantation
- National Institute for Health Research (RCF2013/14-058)
- Roche Organ Transplant Research Foundation
This publication has 60 references indexed in Scilit:
- CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cellsCancer Immunology, Immunotherapy, 2012
- Antibody-Mediated Rejection in Kidney Transplantation: A ReviewJournal of Transplantation, 2012
- Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in miceJCI Insight, 2011
- Ab initio study of MKr n 2+ (M = Cu, Ag, and Au, n = 1-6) clustersJournal of Molecular Modeling, 2011
- Tumor Necrosis Factor Alpha Inhibitors as Immunomodulatory Antirejection Agents after Intestinal TransplantationAmerican Journal of Transplantation, 2011
- Characterization of a rare IL-10–competent B-cell subset in humans that parallels mouse regulatory B10 cellsBlood, 2011
- Pathological and Clinical Characterization of the ‘Troubled Transplant’: Data from the DeKAF StudyAmerican Journal of Transplantation, 2010
- Novel Human Transitional B Cell Populations Revealed by B Cell Depletion TherapyThe Journal of Immunology, 2009
- The Utility of 1- and 3-Month Protocol Biopsies on Renal Allograft Function: A Randomized Controlled StudyAmerican Journal of Transplantation, 2008
- Intraindividual variability in the relative systemic availability of cyclosporin after oral dosingEuropean Journal of Clinical Pharmacology, 1988